CurrentAetnaPolicy 0475

Coblation Clinical Policy Bulletin

Aetna Clinical Policy Bulletin defining medical necessity and investigational/experimental determinations for Coblation procedures across multiple anatomic sites and indications, plus lists of applicable CPT/HCPCS/ICD-10 codes and background/evidence summary. This is part 1 of 4; contains medical necessity statement, experimental/investigational list, related policies, codes for covered and not-covered indications, and extensive background/evidence discussion.

Policy Summary

PayerAetna

PolicyCoblation Clinical Policy Bulletin

Policy CodePolicy 0475

Change TypeNo material change

Effective DateApr 13, 2001

Next Review DateMay 9, 2024

Key ActionDocument that Coblation tonsillectomy is for one of the covered indications (peritonsillar abscess; recurrent middle ear infection with tonsillar hypertrophy as exacerbating factor; recurrent/chronic tonsillar infection; or tonsillar hypertrophy causing respiratory symptoms/airway obstruction).

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this update.

4Covered indications (tonsillectomy)

29+Interventions listed experimental/investigational

MultipleICD-10 codes listed not covered

multiple small studiesEvidence base size (this part)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

YesRCT presence (nasal valve)

Coverage Summary

Scope: Aetna Clinical Policy Bulletin (0475) defines medical necessity and investigational determinations for Coblation procedures across multiple anatomic sites and indications, with lists of applicable CPT/HCPCS/ICD-10 codes and a summary of background evidence (part 1 of 4).

Stance overview: Coverage is mixed — Coblation tonsillectomy is defined as medical necessary for specific indications, while numerous other Coblation applications are considered experimental and investigational; the document’s primary clinical focus and strongest evidence base relate to tonsillectomy, with many other uses remaining preliminary or insufficiently supported.

Key thresholds and policy dates

NOSE Scale responder threshold (primary trial endpoint)>=20% reduction in NOSE total score OR >=1 reduction in NOSE clinical severity category

Alternative NOSE responder threshold (used in some studies)>=15-point improvement on NOSE score

Baseline NOSE eligibility threshold (trial entry)>=55 or >=60 (varied by study; some trials used >=60)

Policy effective date2001-04-13

Last review date2023-07-12

Next review date2024-05-09

Medical-Necessity Criteria

Medical Necessity

Aetna considers Coblation tonsillectomy medical necessary for the treatment of any of the following:

Medical Necessity - indications

Peri-tonsillar abscess.
Recurrent middle ear infection where tonsillar hypertrophy is believed to be an exacerbating factor.
Recurrent or chronic tonsillar infection.
Tonsillar hypertrophy leading to respiratory symptoms or airway obstruction.

Experimental, Investigational, and Not Medically Necessary

Experimental and Investigational (Not Medically Necessary)

Aetna considers the following interventions experimental and investigational because the effectiveness has not been established:

Experimental and Investigational interventions

Cervical Coblation nucleoplasty for the treatment of cervicogenic headache
Coblation adenoidectomy
Coblation annuloplasty for the treatment of cervical discogenic pain
Coblation-assisted arytenoidectomy for the treatment of infants with vocal cord paralysis

Clinical Evidence Summaries

Clinical Evidence Summaries (narrative; no explicit coverage criteria in this part)

This section summarizes clinical studies and level of evidence for various coblation applications:

Clinical Evidence Summaries

Temperature-controlled radiofrequency (TCRF) / Vivaer Nasal Airway Remodeling System for internal nasal valve collapse: multiple single-arm prospective studies, RCT (single-blinded sham-controlled), and long-term follow-up reporting improvement in NOSE scores through 3–48 months; RCT showed superiority to sham at 3 months.
Coblation-assisted arytenoidectomy (CSA / ECPA) for infants with bilateral vocal cord paralysis: small case series and retrospective reviews reporting extubation success and surgical success rates (e.g., Hu et al 2019: 14 patients, 13 extubated; Tan et al 2022: 33 infants, 87.9% surgical success).
RF Coblation for tracheal tumors: case-series (3 cases) showing feasibility; authors call for larger studies.

Coding

CPT codes considered not covered for indications listed in the CPB (examples and ranges provided in document)CPTNot Covered

30465	Repair of nasal vestibular stenosis (eg, spreader grafting, lateral nasal wall reconstruction) [not covered for Vivaer Nasal Airway Remodeling]
30469	Repair of nasal valve collapse with low energy, temperature-controlled (ie, radiofrequency) subcutaneous/submucosal remodeling.
29800-29999	Endoscopy/arthroscopy (other CPT codes related to CPB)
31254-31288	Nasal/sinus endoscopy, surgical; ethmoid, maxillary, frontal, or sphenoid.
31400	Arytenoidectomy or arytenoidopexy, external approach.
31560	Laryngoscopy, direct, operative, with arytenoidectomy.
31561	Laryngoscopy, direct, operative, with arytenoidectomy; with operating microscope or telescope.
42820-42826	Tonsillectomy.
30801-30802	Ablation, soft tissue of inferior turbinates, unilateral or bilateral, any method (eg, electrocautery, radiofrequency ablation, or tissue volume reduction) [listed as CPT codes covered if selection criteria are met]
64633	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance; cervical or thoracic, single facet joint (listed as CPT codes not covered for paravertebral nerve Coblation).

1–10 of 11

1/2

HCPCS / device codes not specifiedHCPCSNot Covered

No specific code

Coblation devices (e.g., Topaz Microdebrider) - no specific HCPCS code listed.

ICD-10 codes covered if selection criteria are metICD-10Covered

J03.00-J03.91	Acute tonsillitis.
J35.01	Chronic tonsillitis.
J35.1	Hypertrophy of tonsils.
J36	Peritonsillar abscess.

ICD-10 codes not covered for indications listed in the CPB (not all inclusive)ICD-10Not Covered

B02.22	Postherpetic trigeminal neuralgia.
B48.1	Rhinosporidiosis.
C10.0-C10.9	Malignant neoplasm of oropharynx.
C32.0-C32.9	Malignant neoplasm of larynx.
C33	Malignant neoplasm of trachea.
D10.6	Benign neoplasm of nasopharynx.
D14.1	Benign neoplasm of larynx [papillomatosis of larynx].
D14.2	Benign neoplasm of trachea [papillomatosis of trachea].
D16.6	Benign neoplasm of vertebral column [spinal osteoid osteomas].
D37.05	Neoplasm of uncertain behavior of pharynx [congenital nasopharyngeal teratoma].

1–10 of 29

1/3

No procedure or billing codes listed in this partmixed

No codes listed

Provider Actions

Documentation Required

Document indication for tonsillectomy

Document the specific indication for Coblation tonsillectomy in the medical record and operative note.

Applicable CPT codes: 42820-42826
Applicable ICD-10 codes (when selection criteria met): J03.00–J03.91 (acute tonsillitis); J35.01 (chronic tonsillitis); J35.1 (hypertrophy of tonsils); J36 (peritonsillar abscess)

Denial Risk

Avoid billing Coblation for investigational indications

Do not bill Coblation procedures for indications listed as experimental/investigational in the policy. Claims submitted with diagnosis codes corresponding to these not-covered indications may be denied.

Example ICD-10 codes from the not-covered list: B02.22 (postherpetic trigeminal neuralgia); G50.0 (trigeminal neuralgia); D16.6 (benign neoplasm of vertebral column); J34.3 (hypertrophy of nasal turbinates); J34.89 (other specified disorders of nose and nasal sinuses); J39.8 (other specified diseases of upper respiratory tract [airway stenosis]); M00.00–M99.9 (diseases of the musculoskeletal system and connective tissue); and others listed in the policy

Definitions

Definitions:

• Coblation: A non-thermal volumetric tissue removal method using a low-temperature plasma generated in conductive fluid that dissociates tissue molecules (plasma-mediated radiofrequency ablation).

• Vivaer: A low-energy bipolar radiofrequency device/system for intranasal remodeling of the internal nasal valve (temperature-controlled RF).

• NOSE Scale: Nasal Obstruction Symptom Evaluation, a validated patient-reported outcome measure for nasal obstruction used as the primary endpoint in many nasal valve studies.

• TCRF / Vivaer: Temperature-controlled radiofrequency device/system used for in-office internal nasal valve remodeling (same technology family as Vivaer).

• Device technology description: Plasma-mediated bipolar radiofrequency tissue ablation/dissolution technology with a low thermal profile (designed to limit temperatures typically <50–60°C) used for tissue removal/ablation with intent to reduce collateral thermal injury.

Evidence Highlights

Study (year/author)	Design / n	Key finding
Silvers et al (2021)	Prospective multicenter randomized, single-blinded RCT; active n=77 vs sham n=41	Responder rate at 3 months: Active 88.3% vs Sham 42.5% (p<0.001); greater mean NOSE score reduction in active arm; 3 possibly related AEs resolved.
William/Yao (2021)	Prospective, multi-center single-arm study; n=122	NOSE score improved from ~80.3 to 32.9 at 3 months (p<0.001); 91.6% had ≥20% improvement or ≥1 severity category improvement.
Jacobowitz et al (2019, 48-month follow-up)	Prospective non-randomized multicenter case-series; initial n=50, extended follow-up n=29	Sustained NOSE improvements through 48 months; baseline 81.0 to 25.7 at 48 months; responder rates ≥92.9% at multiple timepoints (≥15-point improvement threshold).
Han et al (2022)	Prospective randomized single-blinded multicenter trial with crossover; combined active n=108 (77 index + 31 crossover)	At 12 months combined active-treatment responder rate 89.8%; mean NOSE improvement sustained; no device/procedure-related serious AEs reported.
Jacobowitz (initial) / Ephrat (2019/2021)	Prospective non-randomized, multi-center case-series; Jacobowitz n=50; Ephrat extended single-arm cohorts (n up to 49/39)	Mean NOSE decreased from ~79.9 to 24.7 at 26 weeks; high patient satisfaction; studies uncontrolled but show marked short-term benefit.
Luo et al (2020)	Retrospective case series; n=77 (CT-guided percutaneous thoracic nerve root Coblation for PHN)	VAS decreased from 7.22 to ~3.0 at follow-ups; responder rates ~75%-78% across timepoints; mostly mild numbness; no severe AEs reported.
Cochrane review (Burton & Doree, 2007)	Systematic review	Inadequate evidence to determine superiority of coblation tonsillectomy for post-op pain/recovery; audit data suggested possible higher postoperative bleeding; need for large well-designed RCTs and audits.
Belloso et al (2003)	Comparative large cohort study; Coblation n=844 vs traditional n=743	Coblation tonsillectomy associated with less delayed hemorrhage and less post-op pain; fewer secondary infections and lower secondary hemorrhage rates reported.
Arya et al (2003) / Timms & Temple (2002)	Double-blind randomized studies (small): Arya n=14; Timms study noted	Arya RCT: no significant difference in post-op pain between coblation tonsillotomy and coblation tonsillectomy (small n); Timms double-blind RCTs exist supporting evaluation but sample sizes limited.
Guan et al (2022)	Retrospective comparative study; supraglottic carcinoma RFC-TOS n=23 vs open n=23	RFC-TOS had lower operative time, blood loss, faster recovery, lower costs and similar 5-year oncologic outcomes versus open surgery.
Tan et al (2022)	Retrospective review; infants with idiopathic BVCP n=33 undergoing endoscopic Coblation-assisted partial arytenoidectomy (ECPA)	Surgical success 87.9% overall; 95.6% success for BVCP alone vs 70.0% when combined with other airway abnormalities.
Benninger et al (2018, 2022)	Retrospective case-series/cohort; 2018 n=19; 2022 multicenter review n=94	Coblation cordotomy for BVFI showed improvements in breathing/stridor and VHI; 2022 series enabled de-cannulation in 21/25 tracheotomy patients; revision rate ~22%.
Tasto et al (2005) / Velez et al (2022)	Small prospective case series and systematic review for microtenotomy/Coblation in tendinopathy (e.g., lateral epicondylitis)	Studies suggest favorable pain and functional outcomes versus other techniques but evidence is heterogeneous and limited; larger RCTs needed.
Silvers / Yao / William (pooled nasal valve evidence)	Multiple RCTs and single-arm studies (see above) with varied sample sizes	Overall evidence for temperature-controlled RF (Vivaer/TCRF) shows consistent NOSE score improvements and superiority to sham in RCT at 3 months; sustained benefits reported up to 48 months in single-arm follow-ups.

Revision History

2001-04-13effective

Policy effective date. Policy number 0475. Status: CURRENT.

2023-07-12last_reviewLatest

Policy last reviewed. Policy number 0475. Status: CURRENT.

2024-05-09next_review

Next scheduled policy review date. Policy number 0475. Status: CURRENT.

Policy Summary

PayerAetna

PolicyCoblation Clinical Policy Bulletin

Policy CodePolicy 0475

Change TypeNo material change

Effective DateApr 13, 2001

Next Review DateMay 9, 2024

SourceLink

On This Page

Coblation-assisted management of airway stenosis

Coblation-assisted surgical resection for the treatment of rhinosporidiosis

Coblation-assisted turbinoplasty and nasal Coblation plasma surgery for the treatment of allergic rhinitis

Coblation devices (e.g., Topaz Microdebrider) for the treatment of musculoskeletal conditions including insertional Achilles tendinopathy, and lateral epicondylitis

Coblation for soft tissue stenosis of the external auditory canal

Coblation nasal septal swell body reduction for the treatment of nasal obstruction

Coblation non-thermal volumetric tissue reduction for: Dysphagia; Laryngo-tracheal papillomatosis; Nasopharyngeal angiofibroma; Removing soft tissue during arthroscopic surgery; Spinal osteoid osteomas; Wound debridement

Coblation of femoral and sciatic nerve for the treatment of stump pain and phantom limb pain

Computed tomography (CT)-guided percutaneous Coblation of the thoracic nerve root for the treatment of post-herpetic neuralgia

Cordotomy by Coblation for the treatment of vocal fold immobility

CT-guided Gasserian ganglion nerve Coblation for the treatment of trigeminal neuralgia

Endoscopic Coblation cauterization for the treatment of pyriform sinus fistula

Percutaneous disc decompression with Coblation nucleoplasty for the treatment of cervical vertigo

Percutaneous thoracic paravertebral nerve Coblation for the treatment of thoracic neuropathic pain

Radiofrequency (RF) Coblation for the treatment of congenital nasopharyngeal teratoma

RF Coblation-assisted transoral surgery for the treatment of oropharyngeal squamous cell carcinoma, and supraglottic laryngeal carcinoma

RF Coblation for the treatment of glottis cancer

RF Coblation for the treatment of laryngeal cancer

RF Coblation for the treatment of osteochondritis dissecans lesions

RF Coblation for the treatment of peri-scapular tendinopathy

RF Coblation for the treatment of tracheal tumors

RF Coblation, with and without gastrocnemius release, for the treatment of plantar fasciitis

RF to the nasal valve (Vivaer Nasal Airway Remodeling (Aerin Medical)) for the treatment of nasal airway obstruction

Transoral RF Coblation for the treatment of laryngopharyngeal vascular lesions

Videolaryngoscope-assisted Coblation for the treatment of epiglottic cysts

Coverage stance: The policy’s overall stance is mixed, explicitly designating Coblation tonsillectomy as medically necessary for a defined set of indications, and listing numerous other Coblation interventions as experimental and investigational because effectiveness has not been established.

Coding note: Many CPT, HCPCS, and ICD-10 codes are specifically listed as not covered for investigational indications in the policy; detailed coding information and examples are provided in the Coding section of the bulletin.

Coblation devices (Topaz microdebrider) for insertional Achilles tendinopathy and lateral epicondylitis: systematic review and small studies suggesting favorable outcomes vs other surgical techniques but heterogeneous methods and small sample sizes; further RCTs planned/needed.

RFC-assisted transoral surgery (RFC-TOS) for supraglottic laryngeal carcinoma and oropharyngeal squamous cell carcinoma: retrospective comparative studies showing shorter operative time, less blood loss, faster recovery, lower costs vs open surgery with similar oncologic outcomes; authors recommend further trials.

RFC with/without gastrocnemius release for plantar fasciitis: retrospective analyses — evidence incomplete in this excerpt.

Background summary: Coblation is a low-temperature, plasma-mediated radiofrequency tissue-dissociation method intended to remove tissue with less thermal damage than traditional electrosurgery or lasers, using an electrically conductive fluid to generate a plasma layer that dissociates tissue molecules.

Evidence limitations: While the document cites supportive evidence for Coblation tonsillectomy (including randomized and large cohort studies and NICE guidance), it states that evidence is insufficient or preliminary for many other applications (musculoskeletal uses, nucleoplasty, various ENT and pain indications). The strongest evidence outside tonsillectomy is for temperature-controlled radiofrequency/Vivaer for internal nasal valve collapse, but many other uses are based on small case series or nonrandomized studies and require further validation.

Evidence-level metadata (compact)

RCT presence for nasal valve (Vivaer/TCRF)Yes — at least one multi-center single-blinded randomized sham-controlled trial reported

Typical evidence levelMostly Level IV and IIb (single-arm case-series and non-randomized studies) with some RCT (IIb) evidence

Study sample size examplesNasal valve studies up to n=122 (multi-center single-arm) and RCT n=118 (77 active + 41 sham); long-term 48-month cohort n=29

Long-term follow-up example48-month follow-up cohort reported sustained NOSE improvements in n=29

Evidence base size noteMultiple small studies and case series across indications; larger evidence base limited to nasal valve studies

Documentation Required

Use of validated outcome measures in evidence

Document baseline and postoperative NOSE Scale scores when evaluating Coblation (temperature-controlled RF) treatment effectiveness for nasal valve/nasal airway obstruction, as studies used the NOSE Scale as primary patient-reported outcome.

>= 20% reduction in NOSE Scale score or >= 1 reduction in NOSE clinical severity category (primary responder threshold used in many studies)
Alternative responder threshold: >= 15-point improvement on NOSE score (used in some studies)

Documentation Required

Patient selection details referenced in studies

When selecting patients for nasal valve RF treatment, document details that match study eligibility and selection used in the evidence base.

Document that internal nasal valve (nasal valve collapse) is the primary or significant contributor to nasal airway obstruction
Document baseline NOSE Scale score (trials enrolled patients with baseline NOSE >=55–60 when applicable)
Document prior response to temporary nasal valve dilation or lateralization maneuvers if performed (many studies required a positive response)